[go: up one dir, main page]

DK2328931T3 - Selektive anti-hepcidin-25-antistoffer og anvendelser deraf - Google Patents

Selektive anti-hepcidin-25-antistoffer og anvendelser deraf

Info

Publication number
DK2328931T3
DK2328931T3 DK09790908.9T DK09790908T DK2328931T3 DK 2328931 T3 DK2328931 T3 DK 2328931T3 DK 09790908 T DK09790908 T DK 09790908T DK 2328931 T3 DK2328931 T3 DK 2328931T3
Authority
DK
Denmark
Prior art keywords
hepcidin
antibodies
applications
selective anti
selective
Prior art date
Application number
DK09790908.9T
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Ying Tang
Derrick Ryan Witcher
Pia Pauliina Yachi
Peng Luan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2328931T3 publication Critical patent/DK2328931T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK09790908.9T 2008-08-06 2009-07-29 Selektive anti-hepcidin-25-antistoffer og anvendelser deraf DK2328931T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8655708P 2008-08-06 2008-08-06
PCT/US2009/052044 WO2010017070A1 (en) 2008-08-06 2009-07-29 Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK2328931T3 true DK2328931T3 (da) 2013-09-30

Family

ID=41165490

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09790908.9T DK2328931T3 (da) 2008-08-06 2009-07-29 Selektive anti-hepcidin-25-antistoffer og anvendelser deraf

Country Status (20)

Country Link
US (1) US8609817B2 (da)
EP (1) EP2328931B1 (da)
JP (1) JP5730200B2 (da)
KR (1) KR101462307B1 (da)
CN (1) CN102112489B (da)
AU (1) AU2009279865B2 (da)
BR (1) BRPI0916624A2 (da)
CA (1) CA2733497C (da)
DK (1) DK2328931T3 (da)
EA (1) EA201170312A1 (da)
ES (1) ES2432018T3 (da)
HK (1) HK1156326A1 (da)
IL (1) IL210643A (da)
MX (1) MX2011001363A (da)
NZ (1) NZ590863A (da)
PL (1) PL2328931T3 (da)
PT (1) PT2328931E (da)
UA (1) UA103032C2 (da)
WO (1) WO2010017070A1 (da)
ZA (1) ZA201100261B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584947B (zh) * 2003-04-01 2014-03-12 国家健康医学研究所 针对丙型肝炎病毒e1e2 复合体的抗体、hcv 颗粒的组合物和药物组合物
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
KR20180088745A (ko) 2010-08-16 2018-08-06 피어이스 파마슈티컬즈 게엠베하 헵시딘 결합 단백질
EP2791684B1 (en) 2011-12-12 2017-08-23 Pieris Pharmaceuticals GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) * 2012-10-26 2014-05-01 Claresa Levetan Generation of new pancreatic beta cells
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
DK3052522T3 (da) * 2013-10-03 2020-02-24 Biocare Medical Llc Anti-sox 10 antistofsystemer og -fremgangsmåder
JPWO2016027469A1 (ja) * 2014-08-21 2017-06-01 国立大学法人旭川医科大学 ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
NZ730186A (en) * 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016146587A1 (en) 2015-03-13 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
WO2018063963A1 (en) * 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
CA3045857A1 (en) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
CN109948371B (zh) * 2019-03-07 2021-06-25 深圳市智税链科技有限公司 为区块链节点发放身份证书的方法及相关装置
EP4279924A4 (en) * 2021-01-18 2024-06-26 FUJIFILM Corporation HEPCIDIN ABSORPTION INHIBITOR, ABSORPTION INHIBITION METHOD, REFERENCE, REAGENT, KIT, AND MEASUREMENT METHOD

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073454A1 (en) 1999-06-02 2000-12-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
TR201806761T4 (en) 2001-05-25 2018-06-21 Inst Nat Sante Rech Med THE USE OF ALL IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF IRON HOMEOSTASIS DISORDERS.
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
WO2004058044A2 (en) 2002-11-19 2004-07-15 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
CA2531482A1 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
JP2007518062A (ja) 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
MX2007011024A (es) * 2005-03-11 2009-11-23 Vermillion Inc Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin.
AU2008214386B2 (en) 2007-02-02 2013-09-19 Amgen Inc Hepcidin and hepcidin antibodies
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
JP2010539969A (ja) 2007-10-02 2010-12-24 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） ヒトヘプシジンに対して特異性を有する抗原結合タンパク質
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
AU2009246946B2 (en) 2008-05-01 2013-09-26 Amgen Inc. Anti-hepcidin antibodies and methods of use

Also Published As

Publication number Publication date
JP5730200B2 (ja) 2015-06-03
ES2432018T3 (es) 2013-11-29
US8609817B2 (en) 2013-12-17
KR20110031963A (ko) 2011-03-29
UA103032C2 (uk) 2013-09-10
EP2328931B1 (en) 2013-08-14
CA2733497A1 (en) 2010-02-11
KR101462307B1 (ko) 2014-11-17
IL210643A (en) 2015-09-24
EA201170312A1 (ru) 2012-03-30
WO2010017070A1 (en) 2010-02-11
MX2011001363A (es) 2011-04-26
ZA201100261B (en) 2012-06-27
PT2328931E (pt) 2013-11-07
CN102112489A (zh) 2011-06-29
PL2328931T3 (pl) 2014-01-31
CN102112489B (zh) 2014-05-14
CA2733497C (en) 2015-06-02
IL210643A0 (en) 2011-03-31
EP2328931A1 (en) 2011-06-08
AU2009279865B2 (en) 2013-10-10
BRPI0916624A2 (pt) 2015-12-01
US20110189190A1 (en) 2011-08-04
NZ590863A (en) 2012-10-26
AU2009279865A1 (en) 2010-02-11
JP2011530514A (ja) 2011-12-22
HK1156326A1 (en) 2012-06-08

Similar Documents

Publication Publication Date Title
HUS2300039I1 (hu) PSMA-kötõ szerek és alkalmazásaik
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK2240203T3 (da) Alfa5-beta1-antistoffer og deres anvendelser
DK2283041T3 (da) Humaniserede anti-faktor d-antistoffer og anvendelser deraf
DK2281006T3 (da) Tværbindingsmidler og anvendelser deraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
DK2786762T3 (da) Kovalente diabodies og anvendelser deraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HK1196358A1 (zh) 取代的吡啶- -酮和噠嗪- -酮
BRPI0816907A2 (pt) Método e dispositivo
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
DK2129396T3 (da) Antistoffer mod ErbB3 og anvendelser deraf
BRPI0812509A2 (pt) Aparelho reformador e método